ArticleNature and science of sleep2019
A 10-Year Longitudinal Observational Study Of Cataplexy In A Cohort Of Narcolepsy Type 1 Patients.
Article in Nature and science of sleep, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- The effects of caffeine on drowsiness in patients with narcolepsy: a double-blind randomized controlled pilot study.Sleep & breathing = Schlaf & Atmung · 2020Trial
- Article
- The prevalence and incidence of narcolepsy in the United States: a real-world observational study using a validated narcolepsy case definition.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Impact of Age at Narcolepsy Onset on Sleep-Onset REM Periods in the Multiple Sleep Latency Test.Journal of clinical medicine · 2025Article
- Article
- Prevalence and Factors Associated with Rapid Eye Movement-Related Obstructive Sleep Apnea in Patients with Narcolepsy.Nature and science of sleep · 2025Article
- Prevalence and incidence of narcolepsy symptoms in the US general population.Sleep medicine: X · 2023Article
- Differential characteristics of repeated polysomnography and multiple sleep latency test parameters in narcolepsy type 1 and type 2 patients: a longitudinal retrospective study.Sleep & breathing = Schlaf & Atmung · 2022Article
- Body Weight and Metabolic Rate Changes in Narcolepsy: Current Knowledge and Future Directions.Metabolites · 2022Review
- Narcolepsy Type 1: A Remitting Disease? An Unusual Case Report.Nature and science of sleep · 2021Article
- Recognizing the Symptom Spectrum of Narcolepsy to Improve Timely Diagnosis: A Narrative Review.Nature and science of sleep · 2021Review
- Narcolepsy with resolution of cataplexy and persisting orexin deficiency.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Article
- Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy.Current neurology and neuroscience reports · 2020Review
- Neuropsychiatric Correlates of Narcolepsy.Current psychiatry reports · 2020Review
- Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns.Nature and science of sleep · 2020Review
- Medical comorbidities in Saudi patients with narcolepsy: a case-control study.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNarcolepsy type 1 (NT1) is thought to have a chronic persistent course. This study aimed to assess the natural course of cataplexy in patients with NT1 at 2, 6, and 10 years after stabilizing symptoms. Other secondary objectives included assessing sleep quality, body mass index (BMI), and comorbidities at recruitment and 10 years later. PATIENTS AND
methodsCataplexy symptoms, the Epworth sleepiness scale (ESS), sleep quality (assessed using the Pittsburgh sleep quality index [PSQI]), BMI, and comorbid conditions were prospectively monitored in 38 patients with NT1. The study sample comprised 38 patients with narcolepsy (males=27). The mean ages at disease onset and recruitment were 17.7 ± 5.6 years and 24.3 ± 8.6 years, respectively.
resultsIn 42% of the cohort, the anti-cataplectic medications were stopped at the end of the study without disturbing symptoms of cataplexy. Additionally, there was an apparent significant reduction in the frequency of cataplexy over time. The mean ESS score decreased by more than 4 points from 19.4 ± 2.9 to 15 ± 4.3 (p<0.001) while on the same pharmacotherapy. The number of patients with a PSQI score of <5 (indicating good sleep quality) increased from 6 (15.8%) to 15 (39.5%) (p=0.004). The BMI increased from 30 ± 5.1 to 33.3 ± 6 kg/m
conclusionThe findings suggest that the course of NT1 is not stable. Over a 10-year period, cataplexy symptoms improved or disappeared in a large proportion of patients, and there was an improvement in daytime sleepiness and nighttime sleep quality. More prospective studies that repeatedly monitor CSF-HCRT are needed to confirm the current findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.